Meta-analysis of Cinobufacini Injection combined with platinum-contained first-line chemotherapy in treatment of non-small cell lung cancer.
10.19540/j.cnki.cjcmm.20190505.501
- Author:
Yong XU
1
;
Di HAN
1
;
Fan-Chao FENG
1
;
Zhi-Chao WANG
1
;
Cheng GU
1
;
Wen-Pan PENG
1
;
Hai-Lang HE
1
;
Xian-Mei ZHOU
1
Author Information
1. Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing 210029,China.
- Publication Type:Journal Article
- Keywords:
Cinobufacini Injection;
Meta-analysis;
chemotherapy;
non-small cell lung cancer
- MeSH:
Amphibian Venoms/therapeutic use*;
Antineoplastic Combined Chemotherapy Protocols;
Carcinoma, Non-Small-Cell Lung/drug therapy*;
Humans;
Lung Neoplasms/drug therapy*;
Male;
Platinum/chemistry*;
Quality of Life
- From:
China Journal of Chinese Materia Medica
2019;44(21):4728-4737
- CountryChina
- Language:Chinese
-
Abstract:
To systemically evaluate the efficacy and safety of Cinobufacini Injection in combination with platinum-contained first-line chemotherapy for treatment of non-small cell lung cancer(NSCLC). The randomized controlled trials(RCT) about the Cinobufacini in combination with platinum-contained first-line chemotherapy(versus chemotherapy alone) were collected through PubMed,Cochrane library,CNKI,VIP,CBM,and Wan Fang Database from database inception to December 2018. Two researchers extracted data and assessed the literature quality separately,and made a Meta-analysis by using Rev Man 5. 3 software. Twenty-seven RCTs were included in the present review,involving 2 125 patients,1 082 in treatment group and 1 043 in control group. The Meta-analysis results showed that as compared with chemotherapy alone,the combination of Cinobufacini and platinum-contained first-line chemotherapy could enhance one year survival rate(RR = 1. 34,95%CI[1. 17,1. 55],P< 0. 01),two year survival rate(RR = 1. 84,95% CI[1. 31,2. 59],P<0. 01),objective tumor response rate(RR = 1. 47,95%CI[1. 33,1. 63],P<0. 01); improve the quality of life for patients(RR =1. 54,95%CI[1. 37,1. 72],P < 0. 01); and reduce the incidences of WBC toxicity(RR = 0. 63,95% CI[0. 49,0. 80],P < 0. 01),platelet toxicity(RR = 0. 54,95%CI[0. 35,0. 84],P<0. 01),gastrointestinal reactions(RR = 0. 60,95%CI[0. 45,0. 80],P<0. 05),pain(RR = 1. 68,95% CI[1. 38,2. 03],P< 0. 01),and hair loss reaction(RR = 0. 76,95% CI[0. 59,0. 98],P < 0. 05). The results showed that for the treatment of NSCLC,the addition of cinofacini to conventional platinum-contained chemotherapy can increase the long-term and short-term efficacy of chemotherapy,improve the quality of life for patients,and reduce the side effects of platinumbased chemotherapy drugs. However,more high quality and large-scale randomized controlled trials are required to verify this conclusion in the future.
